Analysts at H.C. Wainwright Reiterated their Buy rating for Taro Pharma (TARO) with $124.0000 Target; Nmi Holdings (NMIH) Has 1.5 Sentiment

NMI Holdings, Inc. (NASDAQ:NMIH) Logo

Nmi Holdings Inc (NMIH) investors sentiment decreased to 1.5 in Q4 2017. It’s down -0.34, from 1.84 in 2017Q3. The ratio dived, as 93 investment professionals increased and started new equity positions, while 62 trimmed and sold equity positions in Nmi Holdings Inc. The investment professionals in our database reported: 53.46 million shares, up from 49.15 million shares in 2017Q3. Also, the number of investment professionals holding Nmi Holdings Inc in top ten equity positions was flat from 3 to 3 for the same number . Sold All: 24 Reduced: 38 Increased: 43 New Position: 50.

In a report revealed to clients and investors on 2 April, Taro Pharma (NYSE:TARO) stock Buy was reiterated at H.C. Wainwright. They currently have a $124.0000 price target on the stock. H.C. Wainwright’s price target suggests a potential upside of 25.58% from the company’s last close price.

NMI Holdings, Inc., through its subsidiaries, provides private mortgage guaranty insurance services in the United States. The company has market cap of $1.07 billion. It offers mortgage and pool insurance; reinsurance on loans; and outsourced loan review services to mortgage loan originators. It has a 47.29 P/E ratio.

Analysts await NMI Holdings, Inc. (NASDAQ:NMIH) to report earnings on May, 3. They expect $0.30 earnings per share, up 150.00% or $0.18 from last year’s $0.12 per share. NMIH’s profit will be $19.47 million for 13.79 P/E if the $0.30 EPS becomes a reality. After $0.22 actual earnings per share reported by NMI Holdings, Inc. for the previous quarter, Wall Street now forecasts 36.36% EPS growth.

The stock increased 0.30% or $0.05 during the last trading session, reaching $16.55. About 694,793 shares traded. NMI Holdings, Inc. (NMIH) has risen 49.55% since April 2, 2017 and is uptrending. It has outperformed by 38.00% the S&P500.

Next Century Growth Investors Llc holds 2.85% of its portfolio in NMI Holdings, Inc. for 1.35 million shares. Gator Capital Management Llc owns 167,856 shares or 2.74% of their US portfolio. Moreover, Old West Investment Management Llc has 2.55% invested in the company for 263,201 shares. The California-based Oaktree Capital Management Lp has invested 1.51% in the stock. Pinnacle Holdings Llc, a Oklahoma-based fund reported 135,250 shares.

Taro Pharmaceutical Industries Ltd., a science pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company has market cap of $3.96 billion. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It has a 19.18 P/E ratio. The firm sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.

NMI Holdings, Inc. (NASDAQ:NMIH) Institutional Positions Chart